Has Mark Faries, MD received payments from drug or device companies?

Yes. Drug and device makers reported $83,637 in general payments to Mark Faries, MD across 93 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Faries, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Faries, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Faries, MD

Surgery · New Haven, CTNPI 1659428969

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $60,838 of the $83,637 with a category attached, or 72.7%. 8 manufacturers reported payments, led by Merck at 37.7% of the total. Reporting peaked in 2023 at $36,861 and has fallen 88.9% since, to $4,084 in 2025. Among surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$83,637in general payments, 2019–2025

Across 93 payments — averaging $899.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$32K
E.r. Squibb & Sons, L.L.C.$29K
Regeneron$12K
Regeneron Healthcare Solutions, Inc.$4K
Sanofi$4K
Novartis$3K
plus $290 from 2 others

$2,537,736in research payments, 2019–2025

Across 162 payments — averaging $15,665 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$1.8M
E.r. Squibb & Sons, L.L.C.$432K
Modernatx, Inc.$330K
Organon$720
Amgen$517

What the payments were for

Consulting fees$60,83873%
Speaking & faculty fees$10,25012%
Travel & lodging$9,60411%
Food & beverage$2,9454%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	36	$31,547
E.r. Squibb & Sons, L.L.C.	35	$28,514
Regeneron	11	$12,203
Regeneron Healthcare Solutions, Inc.	4	$4,311
Sanofi	2	$3,905
Novartis	2	$2,868
Iovance Biotherapeutics, Inc.	2	$274
Array Biopharma Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIBTAYO$20,298
KEYTRUDA$5,054
MEKINIST$2,840
TAFINLAR$2,840
Amtagvi$274
OPDIVO$109

How this compares

$83,637 in reported general payments places this provider in the 95th percentile of 289 surgery providers in Connecticut.

See all surgery providers in Connecticut →

Medicare billing

Part B allowed, 2024

$607,983

Medicare patients

408

Services billed

6,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Imiquimod	11	$404

Paid to pharmacies, not to this prescriber.

Other surgery in New Haven

John MortonNew Haven$970K
Andrew DuffyNew Haven$256K
Anees ChagparNew Haven$121K
Kurt RobertsNew Haven$42K
Brian FleischerNew Haven$38K
Brigid KilleleaNew Haven$31K
Maija CheungNew Haven$25K
Grigoriy KlimovichNew Haven$24K
Randal ZhouNew Haven$21K
Mehra GolshanNew Haven$15K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →